Predicting Risk of Plasmodium Vivax Microscopy-Detected Episodes Using Serological Markers in Patients With Plasmodium falciparum Malaria: A Multicountry Diagnostic Performance Evaluation
The Journal of Infectious Diseases · 16.06.2026 · 233 (6) · e1470-e1479
DOI: 10.1093/infdis/jiag164 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 17.03.2026. Verfasst von Maulina Hafidzah und 15 weiteren Autor:innen. Beteiligte Einrichtung: Infection and Global Health Division, WEHI, Parkville, VIC, Australia. Hauptthemen laut MEDLINE: Antibodies, Protozoan, Malaria, Falciparum, Malaria, Vivax, Plasmodium vivax. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Australian Academy of Science Regional Collaborations Program, Bill & Melinda Gates Foundation, National Health and Medical Research Council.
Abstract (Originalsprache)
Background
Plasmodium vivax presents a significant obstacle to malaria elimination due to its capacity to form dormant liver-stage hypnozoites that can cause relapses. Universal radical cure, which administers hypnozoite-targeting treatment to patients with P. falciparum malaria living in co-endemic areas, has potential to reduce P. vivax relapses. However, its implementation is hindered by the lack of a diagnostic tool for detecting hypnozoite-carriage.
Methods
P. vivax serological exposure markers (SEMs) were evaluated as a screening tool in P. falciparum patients for predicting risk of P. vivax microscopy-detected episodes over the following 63 days. Analysis was performed using samples from participants in the PRIMA study from Ethiopia, Indonesia, and Bangladesh (NCT03916003). An existing random forest serological classification algorithm was used and evaluated for sensitivity and specificity, then further optimized by re-training a study-specific model.
Results
IgG antibodies were measured in 244 P. falciparum participant samples, of which 22 had a vivax microscopy-detected episode during follow-up. Serological exposure markers showed high sensitivity (82%) but low specificity (27%), likely due to sustained antibody responses in moderate-to-high transmission areas or undetected submicroscopic P. vivax infections during follow-up. A study-specific algorithm increased specificity to 68%, but with a corresponding drop in sensitivity to 68%.
Conclusions
Although P. vivax SEMs showed limited suitability for guiding radical cure in P. falciparum patients in this study (where the outcome was microscopy-detected vivax episodes), they could play a valuable role in building community trust and acceptance of universal radical cure when supported by strong communication and implementation strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infection and Global Health Division, WEHI, Parkville, VIC, Australia.
- Department of Medical Biology, University of Melbourne, Parkville, VIC, Australia.
- Exeins Health Initiative, Jakarta, Indonesia.
- College of Medicine & Health Sciences, Arba Minch University, Arba Minch, Ethiopia.
- Oxford University Clinical Research Unit, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
- Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
ORCID-Profile: Maulina Hafidzah, Tamiru Shibiru Degaga, Michael Christian, Mohammad Shafiul Alam, J Kevin Baird, Lauren Smith, Dionne C Argyropoulos, Aisah R Amelia, Rintis Noviyanti, Ric N Price, Ivo Mueller, Kamala Thriemer, Rhea J Longley
Förderung
- Australian Academy of Science Regional Collaborations Program
- Bill & Melinda Gates Foundation
- National Health and Medical Research Council
- Victorian Government
- Sylvia and Charles Viertel Charitable Foundation
- Viertel Senior Medical Research
- Gates Foundation
- Australian Centre of Research Excellence in Malaria Elimination
Zitieren
APA
Hafidzah, M., Degaga, T. S., Christian, M., Alam, M. S., Hossain, M. S., Baird, J. K., Sutano, I., Smith, L., Argyropoulos, D. C., Amelia, A. R., Noviyanti, R., Robinson, L. J., Price, R. N., Mueller, I., Thriemer, K., & Longley, R. J. (2026). Predicting Risk of Plasmodium Vivax Microscopy-Detected Episodes Using Serological Markers in Patients With Plasmodium falciparum Malaria: A Multicountry Diagnostic Performance Evaluation. The Journal of Infectious Diseases, 233(6), e1470-e1479. https://doi.org/10.1093/infdis/jiag164
Vancouver
Hafidzah M, Degaga TS, Christian M, Alam MS, Hossain MS, Baird JK, et al. Predicting Risk of Plasmodium Vivax Microscopy-Detected Episodes Using Serological Markers in Patients With Plasmodium falciparum Malaria: A Multicountry Diagnostic Performance Evaluation. The Journal of Infectious Diseases. 2026;233(6):e1470-e1479. doi:10.1093/infdis/jiag164
BibTeX
@article{Hafidzah2026,
author = {Hafidzah, Maulina and Degaga, Tamiru Shibiru and Christian, Michael and Alam, Mohammad Shafiul and Hossain, Mohammad Sharif and Baird, J Kevin and Sutano, Inge and Smith, Lauren and Argyropoulos, Dionne C and Amelia, Aisah R and Noviyanti, Rintis and Robinson, Leanne J and Price, Ric N and Mueller, Ivo and Thriemer, Kamala and Longley, Rhea J},
title = {Predicting Risk of Plasmodium Vivax Microscopy-Detected Episodes Using Serological Markers in Patients With Plasmodium falciparum Malaria: A Multicountry Diagnostic Performance Evaluation},
journal = {The Journal of Infectious Diseases},
year = {2026},
volume = {233},
number = {6},
pages = {e1470--e1479},
doi = {10.1093/infdis/jiag164}
}
EUVIMED